DPH7抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08997(DPH7 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

DPH7 (Diphthamide Biosynthesis 7) is an enzyme involved in the post-translational modification of eukaryotic translation elongation factor 2 (eEF2), a critical protein for ribosomal translocation during protein synthesis. It catalyzes a step in the diphthamide biosynthesis pathway, a conserved modification at a histidine residue (His715 in humans) on eEF2. This modification is targeted by bacterial toxins like diphtheria toxin and Pseudomonas exotoxin A, which ADP-ribosylate eEF2 to inhibit translation.

Antibodies against DPH7 are primarily used to study its role in diphthamide formation, eEF2 function, and cellular responses to translational stress. Research has linked DPH7 dysregulation to diseases, including cancer, as diphthamide deficiency may impair translational fidelity or promote genomic instability. For example, DPH7 mutations or reduced expression have been observed in neuroblastoma and other malignancies, suggesting potential roles in tumorigenesis.

DPH7-specific antibodies enable the detection of protein expression levels, subcellular localization, and interactions in models ranging from yeast to human cells. They are essential tools for elucidating mechanisms of translational regulation, toxin resistance, and DNA damage responses. Recent studies also explore DPH7's involvement in developmental processes and metabolic diseases, highlighting its broader biological significance beyond canonical eEF2 modification. Validated antibodies support both basic research and translational studies aiming to target diphthamide-related pathways for therapeutic interventions.